POINT‐OF‐CARE ANTI‐BCMA CAR T‐CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH‐RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA.

Autor:	Magen, H., Fried, S., Itzhaki, O., Shem‐Tov, N., Danylesko, I., Yerushalmi, R., Marcus, R., Shouval, R., Nevo, L., Shapira‐Frommer, R., Nagler, A., Shimoni, A., Shkury, E., Avigdor, A.
Předmět:	MULTIPLE myeloma T cells CHIMERIC antigen receptors CYTOKINE release syndrome POINT-of-care testing
Zdroj:	Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p82-83, 2p
Abstrakt:	B Introduction: b Anti-BCMA chimeric antigen receptor (CAR) T-cell therapy showed excellent efficacy in patients with relapsed/refractory multiple myeloma (R/R MM). We report outcomes of phase 1b/2 single-center clinical trial of autologous POC anti-BCMA CAR T-cell therapy in patients (pts) with R/R MM treated with >=3 prior therapies (NCT05243212). POINT-OF-CARE ANTI-BCMA CAR T-CELL THERAPY INDUCES ENCOURAGING RESPONSE RATES IN HIGH-RISK RELAPSED/REFRACTORY MULTIPLE MYELOMA. [Extracted from the article]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu Plný text